Given that TRPV4 overactivation contributes to two other key hallmarks of glaucoma pathology —RGC injury and reactive gliosis, both of which are reduced when retinas are subjected to systemic TRPV4 inhibition21, 22, 23, we propose that therapy using TRPV4 antagonists might achieve the hitherto unachievable trifecta in glaucoma treatment by controlling IOP protecting RGCs from mechanical stress and suppressing inflammatory activation of retinal glia. The gene discussed is TRPV4; the disease is glaucoma.